SBMFF (SBMFF) Stock Price & Analysis
SBMFF (SBMFF) rose 0.00% to USD 0.64 as of July 25, 2026 at 13:41 UTC, according to Nexqual real-time market data.
SBMFF last closed at USD 0.64; the session ranged USD 0.64–0.64 on volume of 2,000 shares. Market capitalization is $11.32B, with a 52-week range of USD 0.59–1.24 (PNK). Source: Nexqual, July 25, 2026 at 13:41 UTC.
Key Statistics (as of July 25, 2026 at 13:41 UTC)
| Price | USD 0.64 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.64 |
| Open | USD 0.64 |
| Day Range | USD 0.64 – 0.64 |
| 52-Week Range | USD 0.59 – 1.24 |
| Volume | 2,000 shares |
| Market Cap | $11.32B |
| Exchange | PNK |
Technical Analysis (SBMFF)
Nexqual's technical model rates SBMFF "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 13:41 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 59.89 (neutral) |
| vs SMA50 | Below (USD 0.64) |
| MACD | 0 (positive) |
Analyst Ratings (SBMFF)
Wall Street analysts rate SBMFF "None", per Nexqual as of July 25, 2026 at 13:41 UTC.
| Consensus Rating | None |
|---|
Earnings (SBMFF)
Source: Nexqual, July 25, 2026 at 13:41 UTC.
Financials & Fundamentals (SBMFF)
| Total Revenue | $31.83B |
|---|---|
| Revenue Growth (YoY) | +9.80% |
| Gross Margin | +82.07% |
| Operating Margin | +20.22% |
| Profit Margin | +7.36% |
| ROE | +12.53% |
| Debt / Equity | 38.18 |
| Current Ratio | 1.37 |
| Total Cash | $22.96B |
| Total Debt | $16.07B |
| Free Cash Flow | $6.60B |
Source: Nexqual, July 25, 2026 at 13:41 UTC.
Financial Health Score (SBMFF)
Nexqual rates SBMFF's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 13:41 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 82%, operating 20% |
| Balance Sheet | Solid — $23.0B cash vs $16.1B debt, net cash position |
| Cash Flow | Strong — FCF $6.60B, 21% margin |
| Efficiency | Mixed — ROE 13%, ROA 5.6% |
Ownership (SBMFF)
| Insider Ownership | +48.66% |
|---|---|
| Institutional Ownership | +23.75% |
| Shares Outstanding | 17.77B |
| Float | 8.76B |
Source: Nexqual, July 25, 2026 at 13:41 UTC.
Leadership (SBMFF)
SBMFF is led by S. Y. Tse (age 29), CEO & Executive Director, per Nexqual as of July 25, 2026 at 13:41 UTC.
| CEO & Executive Director | S. Y. Tse (age 29) |
|---|---|
| Founder & Senior Executive Vice Chairman | Ping Tse (age 73) |
| Senior VP & Executive Director | Hsin Tse (age 55) |
| Vice President of Public Affairs & ESG | Song Jin (age 49) |
Major Backers & Investors (SBMFF)
Notable institutional backers of SBMFF include -AB Emerging Markets Opportunities ETF, American Century ETF Trust-Avantis Emerging Markets Equity ETF, DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT., according to Nexqual as of July 25, 2026 at 13:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| -AB Emerging Markets Opportunities ETF | 0.17% |
| American Century ETF Trust-Avantis Emerging Markets Equity ETF | 0.15% |
| DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT. | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.6% |
| BlackRock | 0.86% |
| State Street | 0.11% |
Source: Nexqual, July 25, 2026 at 13:41 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GNMSF | Genmab A/S | USD 274.5 | ▲ 0% |
| UCBJY | UCB S.A. | USD 139.01 | ▼ 0.04% |
| WXIBF | Wuxi Biologics (Cayman) Inc | USD 4.6 | ▲ 0% |
| CMXHF | CSL Ltd. | USD 81.96 | ▲ 0% |
| SFOSF | SHANGHAI FOSUN PHARMACEUTICAL G | USD 2.2 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 13:41 UTC. This page is informational and not investment advice.